Purpose of Investigation: The benefit of comprehensive surgical staging in type I versus type II tumors is investigated and translationally associated with differentially expressed proteins. Materials and Methods: A single institutional database was queried for all uterine cancer patients and sample data was abstracted. Proteins identified from microarray data were further investigated at the immunohistochemical (IHC) level and correlated with sample data. Results: Lymph node dissection did not result in a survival benefit for either type I or type II uterine cancer. L1CAM is differentially expressed between tumor types. GRB7 was found to correlate with stage in type II cancers. Thrombomodulin was expressed at higher levels in all lymph node (LN) positive cancers. Conclusions: LN dissection did not provide a therapeutic benefit in endometrial cancers, especially type II cancers. Protein correlations with stage and histology demonstrate specific biologic profiles. Novel diagnostic and therapeutic targets for differentially expressed tumor proteins are identified.